Pasar al contenido principal

DESARROLLO DE DEGRADADORES “INTELIGENTES” PARA PROTEINAS DE MEMBRANA Y EXTRACELULARES

PID2023-151988OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT RAMON LLULL, FUNDACIO PRIVADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

New Trends in Brain Shuttle Peptides

  • Prades, Roger
  • Teixidó, Meritxell
  • Oller-Salvia, Benjamí
The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood–brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders

  • Escobar Rosales, Montserrat
  • Montaner, Cristina
  • Expòsit, Marc
  • Lucchi, Roberta
  • Díaz-Perlas, Cristina
  • Baker, David
  • Oller-Salvia, Benjamí
The widespread expression of therapeutic targets in both diseased and healthy tissues poses a major challenge for protein-based therapeutics, often leading to dose-limiting side effects. One promising strategy to enhance selectivity is reversible inactivation via affinity masks tethered through cleavable linkers responsive to disease-specific cues. Here, we introduce a workflow for the de novo design of peptide masks that reversibly inactivate miniprotein binders. By extending the C-terminus of the binder with a protease-cleavable linker and a masking helix, we generated minimal constructs that sterically block the receptor-binding interface. We applied this strategy to four therapeutically relevant targets, EGFR domains I and III, FGFR2, and IL7Rα, demonstrating broad applicability. Nearly half of the 20 designs achieved >100-fold affinity reduction, with the most effective mask decreasing EGFR binding by over 3 orders of magnitude. Upon cleavage by tumor-associated proteases, binding was restored in 19 out of 20 cases, confirming reversibility. We further show that micromolar or weaker affinity between the binder and the isolated mask is sufficient for robust inactivation and rapid activation. Additionally, by chemically conjugating a photocleavable linker, we created a light-responsive version of the masked binder, enabling external control with comparable efficiency to protease-sensitive designs. This work establishes a generalizable, rapid, and efficient platform for designing cleavable peptide masks from scratch, paving the way for conditionally active protein therapeutics responsive to endogenous or exogenous stimuli., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders

  • Escobar Rosales, Montserrat
  • Montaner, Cristina
  • Expòsit, Marc
  • Lucchi, Roberta
  • Díaz-Perlas, Cristina
  • Baker, David
  • Oller-Salvia, Benjamí
The widespread expression of therapeutic targets in both diseased and healthy tissues poses a major challenge for protein-based therapeutics, often leading to dose-limiting side effects. One promising strategy to enhance selectivity is reversible inactivation via affinity masks tethered through cleavable linkers responsive to disease-specific cues. Here, we introduce a workflow for the de novo design of peptide masks that reversibly inactivate miniprotein binders. By extending the C-terminus of the binder with a protease-cleavable linker and a masking helix, we generated minimal constructs that sterically block the receptor-binding interface. We applied this strategy to four therapeutically relevant targets, EGFR domains I and III, FGFR2, and IL7Rα, demonstrating broad applicability. Nearly half of the 20 designs achieved >100-fold affinity reduction, with the most effective mask decreasing EGFR binding by over 3 orders of magnitude. Upon cleavage by tumor-associated proteases, binding was restored in 19 out of 20 cases, confirming reversibility. We further show that micromolar or weaker affinity between the binder and the isolated mask is sufficient for robust inactivation and rapid activation. Additionally, by chemically conjugating a photocleavable linker, we created a light-responsive version of the masked binder, enabling external control with comparable efficiency to protease-sensitive designs. This work establishes a generalizable, rapid, and efficient platform for designing cleavable peptide masks from scratch, paving the way for conditionally active protein therapeutics responsive to endogenous or exogenous stimuli., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

New Trends in Brain Shuttle Peptides

  • Prades, Roger
  • Teixidó, Meritxell
  • Oller-Salvia, Benjamí
The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood–brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation., info:eu-repo/semantics/acceptedVersion